Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Bosentan
Treatment for Pulmonary Arterial Hypertension
Typical Dosage: 62.5mg twice daily for 4 weeks, then 125mg twice daily
Effectiveness
75%
Safety Score
55%
Clinical Trials
73
Participants
7K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
62.5mg twice daily for 4 weeks, then 125mg twice daily
Time to Effect
1-3 months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$6,000
Side Effect Mgmt:$800
Total Annual:$16,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$85,000/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$52,500
Cost per Remission
$336,000
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Bosentan in Pulmonary Arterial Hypertension
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
NCT07013149RECRUITING
121 participants
OBSERVATIONAL
São Paulo, Brazil
Started: Aug 20, 2025
Completed Clinical Trials
16 completed trials for Bosentan in Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension
NCT00319267COMPLETEDPHASE3
36 participants
INTERVENTIONAL
Started: May 1, 2005
Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
NCT00319020COMPLETEDPHASE3
33 participants
INTERVENTIONAL
Started: Aug 23, 2005
Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension
NCT01223352COMPLETEDPHASE3
64 participants
INTERVENTIONAL
Started: Mar 8, 2011
BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
NCT00367770COMPLETEDPHASE4
37 participants
INTERVENTIONAL
Boston, United States +16 more
Started: Jan 1, 2004
Bosentan and Pulmonary Endothelial Function
NCT01721564COMPLETEDNA
8 participants
INTERVENTIONAL
Started: Apr 1, 2006
FUTURE 3 Study Extension
NCT01338415COMPLETEDPHASE3
58 participants
INTERVENTIONAL
Aurora, United States +35 more
Started: Mar 8, 2011
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
NCT00303459COMPLETEDPHASE4
334 participants
INTERVENTIONAL
Started: May 1, 2006
Combination Therapy in Pulmonary Arterial Hypertension
NCT00433329COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Started: Mar 1, 2007
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
NCT00323297COMPLETEDPHASE4
105 participants
INTERVENTIONAL
Los Angeles, United States +29 more
Started: Sep 1, 2006
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
NCT01392469COMPLETEDPHASE3
21 participants
INTERVENTIONAL
Tampa, United States +10 more
Started: Apr 20, 2011
Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
NCT00581607COMPLETEDPHASE2, PHASE3
43 participants
INTERVENTIONAL
New York, United States +3 more
Started: Apr 1, 2008
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
NCT04991207COMPLETEDPHASE1
44 participants
INTERVENTIONAL
Berlin, Germany
Started: Feb 6, 2018
Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia
NCT00260819COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Paris, France
Started: Jan 1, 2006
Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets
NCT06484673COMPLETEDPHASE1
32 participants
INTERVENTIONAL
Amman, Jordan
Started: Apr 21, 2024
Pulmonary Artery Remodelling With Bosentan
NCT00595049COMPLETEDPHASE4
11 participants
INTERVENTIONAL
Started: May 1, 2006
The Effect of Tracleer® on Male Fertility
NCT00082186COMPLETEDPHASE4
22 participants
INTERVENTIONAL
Started: Jul 1, 2003
Showing 20 of 73 total trials